Abstract: Despite advances in adjuvant therapy for breast cancer, bone remains the most common site of recurrence. The goal of therapy for these patients is palliative and focused on maximizing the duration and quality of their life, while concurrently minimizing any disease or treatment-related complications. Bone metastases predispose patients to reduced survival, pain, impaired quality of life and the development of skeletal-related events. With an increased understanding of the pathophysiology of bone metastasis, effective treatments for their management have evolved and are now in widespread clinical use. This article will discuss the pathogenesis of bone metastases and review the key clinical evidence for the efficacy and safety of currently available systemic bone-targeted therapies in breast cancer patients with an emphasis on bisphosphonates and the receptor activator of nuclear factor kappa B ligand (RANKL) inhibitors. We will also discuss novel strategies and therapies currently in development.
This is an open access article distributed under the
Creative Commons Attribution License which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
Export to BibTeX
MDPI and ACS Style
Simos, D.; Addison, C.L.; Kuchuk, I.; Hutton, B.; Mazzarello, S.; Clemons, M. Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone Metastases. J. Clin. Med. 2013, 2, 67-88.
Simos D, Addison CL, Kuchuk I, Hutton B, Mazzarello S, Clemons M. Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone Metastases. Journal of Clinical Medicine. 2013; 2(3):67-88.
Simos, Demetrios; Addison, Christina L.; Kuchuk, Iryna; Hutton, Brian; Mazzarello, Sasha; Clemons, Mark. 2013. "Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone Metastases." J. Clin. Med. 2, no. 3: 67-88.